Whiteworth Labs
Executive Summary
Ownership of the generic company is changing hands for a second time in less than 10 months. Investment management firm Locke-Sweatman Investments has acquired a 33% interest in Applied Circuit Technology, Whiteworth's parent company, for between $3 mil. and $5.5 mil. The stake gives the investment firm management control of ACT and Whiteworth. Whiteworth has had sales of about $19 mil. over the last nine months. Locke-Sweatman said it believes "the capacity exists for doubling the revenues of Whiteworth." ACT purchases Whiteworth in March from a private group of investors that bought the generic firm in May 1985 from Whiteworth International.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.